Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E/K||melanoma||sensitive||Trametinib||Phase I||Actionable||In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292; NCT00687622).||22805292|
|BRAF V600E/K||melanoma||sensitive||Trametinib||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011; NCT01245062).||22663011 detail... detail...|
|PubMed Id||Reference Title||Details|
|(22805292)||Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.||Full reference...|
|(22663011)||Improved survival with MEK inhibition in BRAF-mutated melanoma.||Full reference...|
|Mekinist (trametinib) FDA Drug Label||Full reference...|